Purpose of review Molecular and genetic insights into the etiology of autism spectrum disorders are now available. The field now needs to understand how these perturbations affect development and function of the brain.
Introduction
Because autism spectrum disorder (ASD) comprises a group of conditions affecting brain function which have an onset very early in childhood, it is reasonable to assume that all etiologies must interfere with early brain development. From this perspective, I have addressed some of the neurodevelopmental mechanisms whose derailment may lead to ASD. ASD shows no simple or single neuroanatomical phenotype that points to obvious neurodevelopment mechanisms. However, structural neuroimaging and histological studies of individuals with ASD [1] provide evidence for anatomical defects, at least in some individuals, that include increase in cerebrum growth ($10%) during early childhood (years 1-3) with the largest effect in the frontal lobes, the growth rate then decreasing during later childhood. Cerebellar size also increases ($7%) in children under 5 years of age but decreases in older individuals, with reduced cell size and increased density in the 'limbic' areas.
The genetic landscape of ASDs has several salient features [2] [3] [4] . ASDs are heritable -concordance rates in monozygotic twins ($60-90%) are roughly ten-fold higher than in dizygotic twins and siblings. ASDs affect four times as many boys as girls. ASDs are genetically heterogeneous. Defined mutations, genetic syndromes and de-novo copy number variation probably account for about 10-20% of cases; none of these causes individually accounts for more than 1-2% of cases. These known and candidate susceptibility factors can be organized into eight classes of genes: that regulate molecular pathways linking synaptic and nonsynaptic signals with changes in gene expression and protein synthesis, such as TSC1&2 and PTEN; translation and protein stability, and include fragile X (FMR1) and UBE3A; development of neuronal processes and synapses, and include neuroligins (NLGN3 and NLGN4), protocadherin 10 (PCDH10), contactin 3 and 4 (CNTN3 and CNTN4) and CNTNAP2, SHANK3; production and signaling of neurotransmitters and neuromodulators, such as the serotonin transporter (SLC6A4); intracellular ion concentration, such as calcium and sodium channels and a Na þ , K þ /H þ exchanger; metabolism, such as phenylalanine hydroxylase; gene expression such as MeCP2, RNF8, Arx, En2 and Dlx2&5; and genes of unknown function (e.g. AHI1, a cause of Joubert syndrome).
Therefore, ASDs appear to be caused by a large number of genes. Below I describe some models of how to make sense of this genetic complexity; these models are based on developmental and neural pathways that tie together the known molecular/genetic defects that have been associated with ASD.
Neural system dysfunction: localized vs. distributed developmental defects ASD is probably caused by alterations in the structural organization and/or function of neural systems that process social and language information and control complex attentional and cognitive functions. Neural system lesions can be localized or distributed [5] . A localized lesion that weakens or disables one component of a circuit can impede the function of the entire circuit.
Distributed lesions can be caused by defects that are common to many regions of a given neural system, or to multiple neural systems. Examples for this are mutations in FMR1, Rett syndrome (MeCP2) or tuberous sclerosis (TSC1 & 2), which will disrupt neural function throughout the nervous system. Developmental defects can alter the connectivity between brain regions; these can be distributed or localized. Distributed defects include general abnormalities in axon or dendrite growth, synaptogenesis, action potential initiation/propagation and myelination. It is not known whether these types of abnormalities are found in autism, although there is evidence for connectivity defects from functional imaging studies [6] [7] [8] , and from mutations in or near genes that encode proteins implicated in the development of axon tracts: PCDH10 (protocadherin 10) [9] , neurexins/neuroligins [10] , (the autism genome Project Consortium, 2007) and Ig superfamily contactin proteins [9, [11] [12] [13] .
Currently, it is unclear whether or not there are localized connectivity defects in ASD. However, based on analyses of mouse mutants, there are many examples for genetic lesions that selectively alter development of specific brain connections, such as the corpus callosum [14] , or connectivity of axons that comprise the internal capsule [15] [16] [17] [18] . Studies have demonstrated reduced volume of the corpus callosum, relative to total brain volume, in individuals with ASD.
Localized lesions are exemplified by mutation of genes that are expressed in neurons that share common features, such as the Dlx homeobox transcription factors, which regulate the development of most forebrain GABAergic neurons [19 ] , or TBR1, a T-box transcription factor which regulates the development of most early-born cortical glutamatergic neurons [20] . Likewise, localized lesions can be generated by mutations of genes that regulate the development of particular parts of the brain, such as Fgf17 that controls the size and character of the frontal cortex and cerebellum [21] . I will discuss some of these examples below and speculate as to their relevance to some forms of ASD.
FGF genes: core regulators that pattern the growth and nature of the frontal cortex and cerebellum During evolution of the mammalian brain, perhaps the most salient morphological change has been the increased surface area of the neocortex with the concomitant increased laminar complexity of the late-born superficial layers (layers II, III and IV) [22, 23] . The human brain is roughly three times larger than chimpanzee brain. In addition, the prefrontal cortex of humans and greater apes may be disproportionately large compared with the rest of the neocortex of lesser apes, monkeys and less evolved mammals [24, 25] . The prefrontal cortex is the center of complex thinking, planning and decision-making.
Evolutionarily advantageous innovations can also come with liabilities, particularly if selective pressures have not reduced the frequency of design flaws. Thus, perhaps the benefits of the prefrontal cortex enlargement in humans have come with imperfections that underlie some of the etiologies of neuropsychiatric disorders including ASD. Therefore, insights into some forms of ASD may come from understanding the mechanisms that underlie prefrontal-cortex development.
Early in the first year of postnatal life, the brains of individuals with ASD show increased brain volume (and head circumference) [1] . Enlargements are greatest in the frontal lobes. Within the frontal lobe increases are seen in the dorsolateral and medial regions, but not the orbitofrontal cortex. Although retrospective studies of ASD head circumference do not report enlargement at birth, I am unaware of quantitative studies that have documented the size of the prenatal or neonatal ASD brain volume. The mechanisms for ASD brain enlargement are unknown, although insights may come from understanding the basic mechanisms that regulate cortical growth and patterning.
Over the last decade, FGF-signaling has been shown to play a central role in regulating cortical regional properties and growth [26, 27] and in particular promoting development of the frontal cortex [21, [28] [29] [30] . These secreted proteins are produced by patterning centers embedded within the embryonic brain, including at the rostral end of the neural tube [21, 29, 30] . Although Fgf8 has the major role in this process [28, 29] 
À/À mice are viable, but have a subtle reduction in their prefrontal cortex. The defect is selective to the dorsomedial prefrontal cortex, including the anterior cingulate cortex, whereas apparently not affecting the orbitofrontal cortex [21, 30] . Like Fgf8, Fgf17 also patterns the regions flanking the midbrain/hindbrain patterning centerincluding the tectum and the cerebellum [31] . Thus, Fgf17
À/À mice have defects in the prefrontal cortex, inferior colliculus and the cerebellum. In this regard, it is note-worthy that alterations in cerebellar vermis size are seen in ASD [1]. Although there is little understanding of the mechanisms for this, the En2 transcription factor, which lies downstream of FGF-signaling, may contribute to some forms of ASD [32] .
The behavior of Fgf17
À/À mice shed light on the phenotype of individuals with prefrontal cortex, tectal and cerebellar defects. They show deficiencies in assays of social recognition and interaction, as well as reductions in neonatal vocalizations [33 ] . At this point, we cannot directly ascribe these phenotypes to specific neuroanatomical lesions, although it seems very likely that the dorsomedial prefrontal hypoplasia strongly contributes to the social deficits. However, given prefrontal-thalamiccerebellar connectivity [34] , one cannot dismiss the behavioral importance of the cerebellar deficit. Furthermore, the hypoplasia of the inferior colliculus could contribute to the vocalization deficits. In any case, the key point is that lesion of a signal gene (Fgf17) disrupts functions of neural systems required for behaviors that are similar to those that are abnormal in ASD.
The analysis of mutations that reduce expression from Fgf8 and Fgf17 show that these genes promote growth of the cortex, and particularly of the dorsomedial frontal cortex -the region that shows the largest increase in size in ASD [1]. Thus, perhaps, there is over-activity of the FGF-signaling pathway in some forms of ASD. This could be due to several mechanisms, including increased expression of FGF ligands and/or increased signaling through the receptors and downstream transduction pathway. In this regard, mutation of several components that repress this pathway, including the PTEN phosphatase and TSC1/TSC2, are linked to ASD (see below). Of note, PTEN and TSC1/TSC2 regulate many steps in neural development and function, including synaptic signaling.
Detection of salient synaptic information: signal/noise processing Molecular lesions that alter the development and/or function of excitatory, inhibitory and neuromodulatory synapses can disrupt neural systems that mediatecomplex cognitive and social behaviors. For instance, mutations that alter the balance of excitatory and inhibitory synaptic function may impede the ability to detect salient-sensory signals above ambient noise and affect maturation of cortical regions [35] , and have been postulated to contribute to some forms of ASD [36] . For instance, selective-interneuron apoptosis leads to epilepsy in Dlx1 À/À mutants [37] .
The high prevalence of epilepsy in ASD suggests an increase in the excitatory/inhibitory balance. However, current evidence from some mouse models of ASD provides evidence for decreased excitatory/inhibitory balance. For instance, female mice lacking one copy of MeCP2 (the gene responsible for Rett syndrome) show reduced synaptic excitation [38] . Likewise, mice expressing a human allele of Neuroligin3 found in an individual with autism showed increased synaptic inhibition [39] . Currently, it is not known whether these defects are primary changes in synaptic signaling or represent homeostatic responses. Nonetheless, one would expect decreased signal-to-noise (reduced signal salience) in the cortical/hippocampal circuits of these mutants. Therefore, there is good reason to continue exploring the model that disruption of excitatory/inhibitory (E : I) balance, through multiple molecular/cellular mechanisms contributes to ASD. As discussed earlier many of the susceptibility/causative genes regulate synapse formation signaling and homeostasis and therefore have the potential to impact E : I balance. Furthermore, analysis of several mouse mutant 'models' for ASD (including Neuroligin3, Fmr1, MeCP2) have cortical interneuron defects [40 ] .
An approach to identify components of genetic pathways that can contribute to alterations in E : I balance is to decipher transcriptional pathways downstream of transcription factors that control either excitatory or inhibitory neurons. To illustrate this idea, I will briefly highlight insights about the transcriptional control of forebrain inhibitory neuronal development obtained from the analysis of mice bearing mutations of the Dlx homeodomain transcription factors. The Dlx genes are broadly expressed prenatally in progenitors of forebrain GABAergic neurons, as well as postnatally in subsets of mature GABAergic neurons, such as in cortical interneurons [37, 41] . Mutations that simultaneously block the function of pairs of mouse Dlx genes disrupt development (particularly migration and differentiation) of most forebrain GABAergic neurons (including cortical interneurons, and projection neurons of the striatum, pallidum, central nucleus of the amygdala and the reticular nucleus of the thalamus [19 ,42,43] . Although mice lacking pairs of Dlx genes die neonatally, mice lacking Dlx1 are viable. However, after approximately 1 month, there is a selective degeneration of a subset of cortical interneurons that results in reduced cortical inhibition and epilepsy [37] . Thus, Dlx1 À/À mutants have an agedependent onset of seizures analogous to a subset of ASD patients who have late onset of epilepsy [44] , and have deficits in fear conditioning [45 ] . Furthermore, Dlx genes regulate craniofacial morphogenesis, including the ossicles [46, 47] ; as a result, Dlx1 mutants have reduced hearing acuity [48] .
Although heterozygous mutations in the Dlx2 and Dlx5 genes have been detected in some individuals with autism, it is unknown whether these contribute to the development of ASD [49] , or comorbid conditions such as epilepsy. Mice that are heterozygous for Dlx5&6 null mutation have epilepsy, demonstrating that reduced Dlx gene dosage can contribute to pathology (Wang, Baraban and Rubenstein, unpublished).
The Dlx genes directly or indirectly regulate the expression of large numbers of genes that are implicated in GABAergic neuronal development/function. For example, there is evidence that the Arx transcription factor is downstream of Dlx [19 ,50,51] . Mutation of human Arx can cause epilepsy and autism, and in mice results in defects in cortical interneuron development [52] . Dlx genes also promote the expression of glutamic acid decarboxylase and vesicular GABA transporter [19 ,53,54 ] , and thereby will have profound functions in regulating inhibitory tone. Indeed, reduced Dlx dosage is associated with reduced synapse formation and reduced expression of neurexin3, a neuroligin ligand (Cobos, Long and Rubenstein, unpublished) . Dlx repression of the Pak3 kinase is implicated in regulating neurite growth [55] ; human Pak3 mutants have mental retardation [56] . Finally, Dlx genes promote the balance of neuronal vs. oligodendrocyte production, and thereby reduced Dlx function can reduce the number of GABAergic neurons, whereas perhaps altering the extent of myelination [57] .
In brief, the Dlx genes can regulate the development and function of a single generic class of neurons, forebraininhibitory neurons. As such, alterations in the function of the Dlx genes, or of genes downstream of them, can weaken forebrain-inhibitory tone.
Male/female ratio
One of the great mysteries of ASD is the approximately 4 : 1 ratio of affected boys to girls. This could arise because maleness may bias cognitive style, emotional response and instinctual behavior [58] . This bias may sensitize the male brain towards ASD and to the effects of certain alleles or environmental factors.
If this conception were correct how would it arise? Although there are several ASD susceptibility genes on the X chromosome (e.g. Arx, Fmr1, MeCP2, Neuroligin3 and 4), numerically this does not account for the increased male prevalence of ASD. Thus, other models should be considered. Perhaps the simplest model is that male : female hormonal differences, such as brain concentrations of androgens and estrogens, account for the bias (androgens are converted to estrogens in the brain via aromatase; estrogens masculinize neural pathways and sex-specific behaviors [59] . These hormones are potent regulators of behavior and can regulate cell survival and neuronal connectivity and function [60] . In addition estrogens appear to regulate the expression of glutamic acid decarboxylase in the arcuate nucleus of the hypothalamus and thus can modulate GABA signaling [60] . Estrogens also can modulate whether GABA is excitatory or inhibitory, via expression of the potassium-chloride cotransporter KCC2 [61] . Finally, androgens can predispose males to GABAAmediated excitoxicity [62] . Therefore, sex steroids could modulate excitatory/inhibitory balance, which could sensitize the male brain to ASD. This raises the possibility that the modulation of sex-steroid signaling in men with severe forms of ASD might be of therapeutic value.
Conclusion
Major progress is currently being made in identifyingmolecular mechanisms that predispose the developing brain to ASD. In this article, I have proposed three models that could account, at least in part, for the neural basis of ASD. I hope that the three developmental models proposed herein, in addition to models involving synapse formation/function/maintenance are useful for conceptualizing how these specific molecular lesions could disrupt neural systems underlying the cognitive, emotional and social deficits observed in ASD.
